ACE-031 vs Trenbolone
Emerging vs Moderate Research
monitor Mechanism-based · 46% Both ACE-031 and Trenbolone suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone.
Molecular Data
ACE-031 Trenbolone
Weight — 270.37 Da (base)
Half-life 12-15 days ~3 days (acetate)
Type Soluble activin receptor type IIB-Fc fusion protein 19-nortestosterone derivative (C18H22O2), trienone steroid
Key Benefits
ACE-031
01 Significant lean mass increases (up to 1.7% in 29 days) observed in Phase 1 trials
02 Simultaneous reduction in fat mass alongside muscle gains
03 Long half-life (12-15 days) allows infrequent dosing
04 Broad TGF-beta ligand neutralization for robust anti-catabolic effects
05 Dose-dependent increases in thigh muscle volume confirmed by MRI
Trenbolone
01 Exceptional lean muscle mass accrual with minimal water retention due to non-aromatizing profile
02 Dramatic body recomposition capability -- simultaneous muscle gain and fat loss even in caloric deficit
03 Approximately five times the anabolic and androgenic potency of testosterone (500:500 ratio)
04 Powerful anti-catabolic effects through glucocorticoid receptor antagonism, protecting muscle during dieting
05 Significant increases in strength across all compound movements, often rapid in onset
06 Enhanced nutrient partitioning, directing calories toward lean tissue accretion over fat storage
07 Pronounced muscle hardness, density, and vascularity due to absence of estrogenic water retention
08 Increased IGF-1 production in muscle tissue, amplifying growth signaling pathways
Dosing Protocols
ACE-031
0.5-3 mg/kg IV every 2 weeks (clinical research doses only) / Every 2 weeks
Phase 1 Research Protocol (Healthy Volunteers) 0.1-3 mg/kg Single IV dose
Phase 2 Research Protocol (DMD) 0.5-2.5 mg/kg Every 2 weeks
Trenbolone
200-400 mg/week / Every other day (acetate) or 2x per week (enanthate)
Recomposition - Moderate (Acetate) 200-300 mg/week (50-75 mg every other day) Every other day
Advanced Cutting (Acetate) 300-400 mg/week (75-100 mg every other day) Every other day
Lean Bulk (Enanthate) 200-400 mg/week 2x per week
Contest Preparation - Advanced 300-500 mg/week Every other day (acetate) or 2x per week (enanthate)
Side Effects
ACE-031
Nosebleeds (epistaxis) - most frequently reported adverse event
Gum bleeding
Telangiectasia (dilated small blood vessels visible on skin)
Skin erythema (redness)
Minor injection site reactions
Trenbolone
Insomnia and severely disrupted sleep architecture (one of the most universally reported side effects, affecting the majority of users)
Night sweats, often drenching, requiring sheet changes
Significantly reduced cardiovascular endurance and aerobic capacity
Increased aggression, irritability, and shortened temper
Anxiety and restlessness, particularly at higher doses
Tren cough: acute, intense coughing fit lasting 30-90 seconds immediately after injection, caused by a small amount of oil entering a blood vessel
Dark-colored urine (oxidized metabolites; not necessarily indicative of kidney damage but should be monitored)
Elevated body temperature and increased sweating throughout the day
Acne and oily skin, particularly on shoulders, back, and chest
Accelerated hair loss in those genetically predisposed to male pattern baldness
Profoundly suppressive of natural testosterone production (near-complete HPT axis shutdown)
Increased heart rate and elevated blood pressure
Contraindications
NEVER approved for human use - clinical development discontinued
History of bleeding disorders or vascular malformations
Concurrent anticoagulant or antiplatelet therapy
Known hypersensitivity to Fc fusion proteins
Pregnancy or breastfeeding
First steroid cycle or limited anabolic steroid experience (trenbolone is strictly an advanced-only compound)
Pre-existing cardiovascular disease, cardiomyopathy, or significant cardiac risk factors
History of mental health conditions: anxiety disorders, depression, bipolar disorder, or psychotic episodes
Liver disease or significantly elevated liver enzymes
Kidney disease or impaired renal function
Uncontrolled hypertension
Polycythemia (hematocrit above 54% at baseline)
Prostate cancer or history of hormone-sensitive cancers
Active or recent substance abuse (trenbolone's psychological effects can exacerbate addictive behaviors)
Pregnancy or potential for pregnancy in female partners (extremely virilizing compound)
Research Evidence
ACE-031 Trenbolone
Status Emerging Moderate Research
References 4 studies 5 studies
Latest — January 2023
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.